HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3173-3184

  Getz, G S ^a   Wool, G D ^a   Reardon, C A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoa i; Apoproteins; Atherosclerosis; HDL; Inflammation; Mimetic peptides

Indexed keywords

ABC TRANSPORTER A1; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; AT 15261; CLUSTERIN; D4F; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN APOLIPOPROTEIN RELATED PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE 2; L4F; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SERUM AMYLOID A; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALPHA HELIX; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHRONIC DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY DISEASE; LIPID OXIDATION; MACROPHAGE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEPSIS; VASODILATATION; VIRUS INFECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS; ATHEROSCLEROSIS; CHOLESTEROL; CLUSTERIN; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MOLECULAR MIMICRY; PEPTIDES; PROTEIN STRUCTURE, SECONDARY;

EID: 78649861855     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292492     Document Type: Article

References (81)

1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Circulation 1989; 79: 8-15.
2. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1994; 91: 9607-11.
3. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2008; 51: 2199-211.
4. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: Beyond reverse cholesterol transport. Curr Drug Targets 2008; 9: 196-203.
5. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev 2009; 6: 455-63.
6. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trail. JAMA 2003; 290: 2292-300.
7. Tardif JC, Grégoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary artery atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-82.
8. Li WH, Tanimura M, Luo CC, Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res 1988; 29: 245-71.
9. Anantharamaih GM, Jones JL, Brouillette CG, et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidycholine. J Biol Chem 1985; 260: 10248-55.
10. Yancey PG, Bielicki JK, Johnson WJ, et al. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995; 34: 7955-65
11. Venkatachalapathi YV, Phillips MC, Epand RM, Epand RF, Tytler EM, Segrest JP, Anantharamaiah GM. Effect of end group blockage on the properties of class A amphipathic helical peptides. Proteins 1993; 15: 349-59
12. Mishra VK, Palgunachari MN, Segrest JP, Anantharamaiah GM. Interactions of synthetic peptide analogs of the class A amphipathic helix. J Biol Chem 1994; 269: 1785-91.
13. Epand RM, Gawish A, Iqbal M, et al. Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin: cholesterol acyltransferase activation. J Biol Chem 1987; 260: 10248-55.
14. Mishra VK, Anantharamaih GM, Segrest JP, et al. Association of a model class A (apolipoprotein) amphipathic α helical peptide with lipid. High resolution NMR studies of peptide-lipid discoidal complexes. J Biol Chem 2006; 281: 6511-9.
15. Anantharamaiah GM, Mishra VK, Garber DW, et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007; 48: 1915-23.
16. Datta G, Chaddha M, Hama S, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42: 1096-104.
17. Datta G, Epand RF, Epand RM, et al. Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity. J Biol Chem 2004; 279: 26509-17.
18. Handattu SP, Garber DW, Horn DC, et al. ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem 2007, 282: 1980-8.
19. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-8.
20. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-508.
21. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-46.
22. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-6.
23. Van Lenten BJ, Wagner AC, Jung CL, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49: 2302-11.
24. Remaley AT, Thomas F, Stonik JA, et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1- dependent and an ABCA1-independent pathway. J Lipid Res 2003; 44: 828-36.
25. Navab M, Ruchala P, Waring AJ, et al. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all Lamino acids. J Lipid Res 2009, 50: 1538-47.
26. Tang C, Vaughan AM, Anantharamaiah GM, Oram JF. Janus kinase 2 modulates the lipid-removing but not protein stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res 2006; 47: 107-14.
27. Garber DW, Handattu SP, Datta G, et al. Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol 2006; 7: 235-40.
28. Getz GS, Wool GD, Reardon CA. Apolipoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr Opin Lipidol 2009; 20: 171-5.
29. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an antiinflammatory receptor. J Biol Chem 2009; 284: 32336-43.
30. Yvan-Charvet L, Welch C, Palger TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages. Free cholesterol accumulation, increased signaling via Toll-like receptors, and neutophil infiltration of atherosclerotic lesions. Circulation 2008; 118: 1837-47.
31. Navab M, Anantharamaih GM, Reddy ST, et al. Oral D-4F causes formation of pre-?? high-density lipoprotein and improves highdensity lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: 3215-20.
32. Troutt JS, Alborn WE, Mosior MK, et al. An apolipoprotein A-I mimetic dose-dependently increased the formation of preβ1 HDL in human plasma. J Lipid Res 2008; 49: 581-7.
33. Wool GD, Reardon CA, Getz GS. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially antiatherogenic properties. J Lipid Res 2008; 49: 1268-83.
34. Navab N, Anantharamaih GM, Reddy ST, et al. Apolipoprotein AI mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25: 1325-31.
35. Wool GD, Vaisar T, Reardon CA, Getz GS. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J Lipid Res 2009; 50: 1889-900.
36. Navab M, Shechter I, Anantharamaih GM, Reddy ST, Van Lenten BJ, Fogelman AM. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010; 30: 164-8.
37. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 1994; 94: 1698-705.
38. Sethi AA, Stonik JA, Thomas F, et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 2008; 283: 32273-82.
39. Dashti N, Datta G, Manchekar M, Chaddha M, Anantharamaiah GM. Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells. J Lipid Res 2004, 45: 1919-28.
40. Tabet F, Remaley AT, Segaliny AI, et al. The 5A apolipoprotein A-I mimetic peptide displays anti-inflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 2010; 30: 246-52.
41. Natarajan P, Forte RM, Chu B, Phillips MC, Oram JF, Bielicki JK. Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem 2004; 279: 24044-52.
42. Jones SE, Jomary C. Molecules in focus: Clusterin. Int J Biochem Cell Biol 2002; 34: 427-31.
43. de Silva HV, Stuart WD, Duvic CR, et al. A 70-kDa apolipoprotein designated apoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990; 265: 13240-7.
44. Navab M, Hama-Levy S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-9.
45. Navab M, Anantharamaiah GM, Reddy ST, et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1932-7.
46. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver and artery wall. J Lipid Res 2009; 50: S156-61.
47. Mahley RW, Weisgraber K, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009; 50: S183-8.
48. Nikoulin IR, Curtiss LK. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J Clin Invest 1998; 101: 223-34.
49. Datta G, Chaddha DW, Chung BH, et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000; 39: 213-20.
50. Datta G, Garber DW, Chung BH, et al. Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res 2001; 42: 959-66.
51. Gupta H, White R, Handattu S, et al. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe Heritable Hyperlipidemic rabbits. Circulation 2005; 111: 31112-8.
52. Vedhachalam C, Narayanaswami V, Neto N, et al. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 2007; 46: 2583-93,
53. Bielicki JK, Zhang H, Cortez Y, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010; 51: 1496-503.
54. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res 1996; 37: 2662-74.
55. Stonik JA, Remaley AT, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun 2004; 321: 936-41.
56. Kisilevsky R, Tam SP. Macrophage cholesterol efflux and the active domains of serum amyloid A2.1. J Lipid Res 2003; 44: 2257-69.
57. Tam SP, Ancsin JB, Tan R, Kisilevsky R. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/- mice. J Lipid Res 2005; 46: 2091-101.
58. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in apoE null mice. Circ Res 2005; 97: 524-32.
59. Navab M, Anantharamaih GM, Fogelman AM. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med 2008; 18: 61-6.
60. Van Lenten BJ, Wagner AC, Navab M, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human Type II pneumocytes. Circulation 2004; 110: 3252-8.
61. Zhang Z, Datta G, Zhang Y, et al. Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol 2009; 297: H866-73.
62. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-2.
63. Li X, Chyu KY, Faria Neto JR, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110: 1701-5.
64. Navab M, Anantharamaiah GM, Hama S, Hough G, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1426-32.
65. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42: 545-52.
66. Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107: 2337-41.
67. Ou J, Wang J, Xu H, Ou Z, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005; 97: 1190-7.
68. Tabet F, Remaley AT, Segaliny AI, et al. The 5A apolipoprotein A-I mimetic peptides displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 2010; 30: 246-52.
69. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an antiinflammatory receptor. J Biol Chem 2009; 284: 32336-43.
70. Efrat M, Aviram M. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a potential role for HDL phospholipids. Adv Exp Med Biol 2010; 660: 153-66.
71. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 2003; 44: 780-92.
72. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
73. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49: 1344-52.
74. Garber DW, Handattu S, Aslan I, Datta G, Chaddha M, Anantharamaiah GM. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 2003; 1689: 229-37
75. Chung BH, Anantharamaiah GM, Brouillette CG, Nishida T, Segrest JP. Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with functions. J Biol Chem 1985, 260: 10256-62.
76. Datta G, White CR, Dashti N, et al. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18ANH2. Atherosclerosis 2010; 208: 134-41.
77. Garber DW, Venkatachalapathi YV, Gupta KB, et al. Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Arterioscler Thromb 1992; 12: 886-94.
78. Van Lenten BJ, Wagner AC, Navab M, et al. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007; 48: 2344-53.
79. Besler C, Heinrich K, Riwanto M, Luscher TF, Landmesser U. High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial- Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease. Curr Pharm Des 2010; 16(13): 1480-93.
80. Meurs I, Van EM, Van Berkel TJ. HDL: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis. Curr Pharm Des 2010; 16(13): 1445-67.
81. Petraki MP, Mantani PT, Tselepis AD. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides. Curr Pharm Des 2009; 15(27): 3146-66.